Vismodegib for Locally Advanced Periocular and Orbital Basal Cell Carcinoma: A Review of 15 Consecutive Cases

Basal cell carcinoma (BCC) is the most common periocular skin cancer and can lead to significant morbidity. We assess the effectiveness of vismodegib, a first-in-class Hedgehog signaling pathway inhibitor, in the management of periocular and orbital BCCs based on clinical response, tolerability, and...

Descripción completa

Detalles Bibliográficos
Autores principales: Wong, Kai Yuen, Fife, Kate, Lear, John T., Price, Richard D., Durrani, Amer J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2017
Materias:
Ideas and Innovations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5548583/
https://www.ncbi.nlm.nih.gov/pubmed/28831360
http://dx.doi.org/10.1097/GOX.0000000000001424

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5548583/
https://www.ncbi.nlm.nih.gov/pubmed/28831360
http://dx.doi.org/10.1097/GOX.0000000000001424

Ejemplares similares